Skip to main content

NYSE:NVS - Novartis Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $108.50
  • Forecasted Upside: 23.35 %
  • Number of Analysts: 12
  • Breakdown:
  • 2 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$87.96
▲ +0.61 (0.70%)
1 month | 3 months | 12 months
Get New Novartis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$108.50
▲ +23.35% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is $108.50, with a high forecast of $112.00 and a low forecast of $105.00. The average price target represents a 23.35% upside from the last price of $87.96.

Hold

The current consensus among 12 polled investment analysts is to hold stock in Novartis. This rating has held steady since March 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 3 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 2 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 2 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 2 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 2 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 2 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 2 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/28/2021JPMorgan Chase & Co.Reiterated RatingUnderweightLow
i
4/28/2021Oddo BhfUpgradeNeutral ➝ OutperformLow
i
4/19/2021UBS GroupReiterated RatingBuyLow
i
3/23/2021Societe GeneraleReiterated RatingBuyLow
i
3/22/2021Sanford C. BernsteinInitiated CoverageMarket PerformMedium
i
3/16/2021ArgusReiterated RatingBuy ➝ HoldLow
i
3/10/2021ArgusDowngradeBuy ➝ HoldLow
i
2/2/2021Morgan StanleyReiterated RatingOverweightLow
i
2/1/2021CowenDowngradeOutperform ➝ Market Perform$110.00 ➝ $105.00Low
i
1/22/2021BarclaysReiterated RatingUnderweightMedium
i
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuyLow
i
1/8/2021Morgan StanleyReiterated RatingOverweightLow
i
12/3/2020ArgusBoost Price Target$100.00 ➝ $112.00Low
i
11/25/2020UBS GroupReiterated RatingBuyLow
i
11/10/2020JPMorgan Chase & Co.Reiterated RatingUnderweightLow
i
9/29/2020Berenberg BankInitiated CoverageBuyMedium
i
9/23/2020Oddo BhfDowngradeBuy ➝ NeutralLow
i
9/10/2020UBS GroupUpgradeNeutral ➝ BuyLow
i
9/1/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightHigh
i
8/12/2020JPMorgan Chase & Co.Reiterated RatingUnderweightLow
i
7/28/2020Morgan StanleyReiterated RatingEqual WeightLow
i
6/15/2020CitigroupUpgradeNeutral ➝ BuyLow
i
5/11/2020UBS GroupReiterated RatingNeutralMedium
i
4/29/2020JPMorgan Chase & Co.Reiterated RatingUnderweightLow
i
4/29/2020BarclaysReiterated RatingUnderweightLow
i
4/23/2020Morgan StanleyReiterated RatingEqual WeightLow
i
4/3/2020The Goldman Sachs GroupReiterated RatingBuy$116.00High
i
Rating by Keyur Parekh at The Goldman Sachs Group, Inc.
3/10/2020Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
i
2/25/2020GuggenheimDowngradeBuy ➝ NeutralHigh
i
2/17/2020CitigroupDowngradeBuy ➝ NeutralLow
i
10/25/2019CowenReiterated RatingBuy$100.00Low
i
8/29/2019Jefferies Financial GroupReiterated RatingBuyLow
i
7/23/2019ArgusBoost Price TargetBuy$105.00Low
i
7/23/2019Kepler Capital MarketsDowngradeBuy ➝ HoldLow
i
7/5/2019JPMorgan Chase & Co.Reiterated RatingSellMedium
i
4/25/2019Liberum CapitalUpgradeHold ➝ BuyLow
i
4/24/2019GuggenheimUpgradeNeutral ➝ Buy$79.16Medium
i
4/10/2019Morgan StanleyDowngradeEqual Weight ➝ Underweight$82.50 ➝ $82.52Low
i
1/29/2019JPMorgan Chase & Co.Reiterated RatingSellLow
i
1/16/2019JPMorgan Chase & Co.Reiterated RatingSellLow
i
1/2/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
i
12/20/2018Credit Suisse GroupDowngradeSellLow
i
Rating by Matthew Weston at Credit Suisse Group AG
12/11/2018Jefferies Financial GroupReiterated RatingBuy ➝ Buy$105.00Low
i
12/7/2018BarclaysDowngradeEqual Weight ➝ SellLow
i
12/2/2018CowenUpgradeMarket Perform ➝ Outperform$88.03Low
i
11/28/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
11/26/2018CowenUpgradeMarket Perform ➝ Outperform$100.00Low
i
11/16/2018The Goldman Sachs GroupUpgradeNeutral ➝ Conviction-BuyLow
i
11/6/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
10/23/2018Wolfe ResearchInitiated CoverageOutperformMedium
i
10/18/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
10/11/2018JPMorgan Chase & Co.Reiterated RatingNeutralHigh
i
10/10/2018The Goldman Sachs GroupReiterated RatingNeutralMedium
i
10/8/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
i
9/11/2018BNP ParibasUpgradeUnderperform ➝ NeutralLow
i
9/11/2018Exane BNP ParibasUpgradeUnderperform ➝ NeutralLow
i
9/11/2018CitigroupUpgradeNeutral ➝ BuyLow
i
9/10/2018Bank of AmericaUpgradeUnderperform ➝ Buy$74.71Low
i
7/19/2018BarclaysUpgradeUnderweight ➝ Equal WeightLow
i
7/19/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
7/19/2018DZ BankReiterated RatingBuyLow
i
5/29/2018HSBCDowngradeBuy ➝ HoldLow
i
5/25/2018Credit Suisse GroupUpgradeUnderperform ➝ NeutralLow
i
5/17/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
4/20/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralLow
i
4/10/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralLow
i
4/9/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
1/18/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
1/15/2018UBS GroupReiterated RatingNeutralLow
i
1/2/2018Nord/LBReiterated RatingNeutralMedium
i
12/27/2017Nord/LBReiterated RatingNeutralLow
i
12/6/2017Bank of AmericaDowngradeNeutral ➝ UnderperformLow
i
10/31/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
10/25/2017BarclaysDowngradeEqual Weight ➝ UnderweightN/A
i
Rating by Emmanuel Papadakis at Barclays PLC
10/24/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
10/23/2017SVB LeerinkBoost Price TargetMarket Perform$89.00 ➝ $91.00N/A
i
10/10/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
9/26/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
9/5/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
8/29/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
8/9/2017CowenSet Price TargetHold$90.00Medium
i
Rating by Steve Scala at Cowen Inc
7/26/2017Morgan StanleyUpgradeUnderweight ➝ OverweightLow
i
7/18/2017CowenReiterated RatingHoldLow
i
Rating by Steve Scala at Cowen Inc
7/17/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
7/11/2017CowenSet Price TargetHold$77.00Low
i
Rating by Steve Scala at Cowen Inc
7/10/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
7/5/2017Credit Suisse GroupDowngradeNeutral ➝ Underperform$82.25Medium
i
Rating by Rebekah Harper at Credit Suisse Group AG
6/22/2017SVB LeerinkReiterated RatingMarket Perform$83.00Low
i
6/22/2017BarclaysUpgradeUnderweight ➝ Equal WeightLow
i
Rating by Emmanuel Papadakis at Barclays PLC
6/22/2017JPMorgan Chase & Co.Reiterated RatingNeutralHigh
i
Rating by Richard Vosser at JPMorgan Chase & Co.
6/16/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
Rating by Richard Vosser at JPMorgan Chase & Co.
6/8/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
Rating by Richard Vosser at JPMorgan Chase & Co.
6/6/2017Morgan StanleyReiterated RatingSellLow
i
6/2/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
Rating by Richard Vosser at JPMorgan Chase & Co.
5/30/2017UBS GroupReiterated RatingNeutralN/A
i
5/24/2017UBS GroupReiterated RatingNeutralN/A
i
4/18/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
Rating by Richard Vosser at JPMorgan Chase & Co.
4/5/2017CowenDowngradeOutperform ➝ Market Perform$87.00 ➝ $77.00Low
i
3/23/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
Rating by Richard Vosser at JPMorgan Chase & Co.
3/22/2017The Goldman Sachs GroupReiterated RatingNeutralLow
i
3/14/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
Rating by Richard Vosser at JPMorgan Chase & Co.
3/9/2017Liberum CapitalInitiated CoverageBuy ➝ BuyLow
i
3/7/2017BarclaysInitiated CoverageUnderweightN/A
i
3/7/2017Societe GeneraleUpgradeHold ➝ Buy$73.82 ➝ $74.37N/A
i
3/7/2017BNP ParibasDowngradeNeutral ➝ UnderperformN/A
i
1/31/2017ArgusUpgradeHold ➝ BuyN/A
i
1/25/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
Rating by Richard Vosser at JPMorgan Chase & Co.
1/19/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
Rating by Richard Vosser at JPMorgan Chase & Co.
1/17/2017Berenberg BankDowngradeBuy ➝ HoldN/A
i
1/11/2017Credit Suisse GroupDowngradeOutperform ➝ NeutralN/A
i
1/9/2017Deutsche Bank AktiengesellschaftReiterated RatingNeutralN/A
i
1/3/2017JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralN/A
i
12/13/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
11/18/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
11/10/2016ArgusUpgradeHold ➝ Buy$85.00N/A
i
10/27/2016Societe GeneraleReiterated RatingHoldN/A
i
10/24/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
10/16/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
10/10/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 ➝ $92.00N/A
i
9/20/2016Chardan CapitalInitiated CoverageBuy$95.00N/A
i
9/13/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
8/25/2016ArgusReiterated RatingHoldN/A
i
Rating by John Eade at Argus
7/19/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
7/13/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
7/12/2016Bank of AmericaReiterated RatingHoldN/A
i
Rating by Graham Parry at Bank of America Co.
5/26/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
5/24/2016CitigroupReiterated RatingNeutralN/A
i
5/19/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
5/18/2016Bank of AmericaReiterated RatingHoldN/A
i
Rating by Graham Parry at Bank of America Co.
5/18/2016CitigroupReiterated RatingNeutralN/A
i
5/13/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
(Data available from 5/9/2016 forward)
Novartis logo
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Read More

Today's Range

Now: $87.96
$87.69
$88.17

50 Day Range

MA: $86.87
$85.18
$88.66

52 Week Range

Now: $87.96
$77.04
$98.52

Volume

2,048,575 shs

Average Volume

1,981,185 shs

Market Capitalization

$201.31 billion

P/E Ratio

28.47

Dividend Yield

2.38%

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Novartis?

The following sell-side analysts have issued stock ratings on Novartis in the last twelve months: Argus, Barclays PLC, Berenberg Bank, Citigroup Inc., Cowen Inc, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Oddo Bhf, Sanford C. Bernstein, Societe Generale, and UBS Group AG.
View the latest analyst ratings for NVS.

What is the current price target for Novartis?

2 Wall Street analysts have set twelve-month price targets for Novartis in the last year. Their average twelve-month price target is $108.50, suggesting a possible upside of 23.4%. Argus has the highest price target set, predicting NVS will reach $112.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $105.00 for Novartis in the next year.
View the latest price targets for NVS.

What is the current consensus analyst rating for Novartis?

Novartis currently has 2 sell ratings, 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVS, but not buy more shares or sell existing shares.
View the latest ratings for NVS.

What other companies compete with Novartis?

How do I contact Novartis' investor relations team?

Novartis' physical mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company's listed phone number is 41-61-324-1111 and its investor relations email address is [email protected] The official website for Novartis is www.novartis.com.